, Reuber (1960) and Glucksmann and Cherry (1966) have reported it.
THE induction of malignant neoplasms in the salivary glands of rats varies with sex and can be modified by castration and by administration of sex hormones (Glucksmann and Cherry, 1966) . For the same dose of the carcinogen tumour incidence is greater in males than in females, and is reduced in males by oestrogens and increased in females by testosterones. At this dose level sarcomas and carcinomas are elicited in equal proportions in males, while in females twice as many sarcomas as carcinomas are induced. The present investigation is concerned with the effect of varying the carcinogenic dosage on the sex difference in tumour induction and the proportion of resulting sarcomas and carcinomas.
Experiments on careinogenesis in the cervico-vaginal tract of rats have shown that the incidence of sarcomas increases with increasing numbers of weekly applications of the carcinogen, but there is an optimal level of dosage for the induction of epithelial tumours and subsequent inhibition of tumour formation (Glucksmann and Cherry, 1970a and b). If salivary gland tumours behave similarly, doubling the concentration of the carcinogen might be expected to increase the incidence of sarcomas but to reduce that of carcinomas, while halving the concentration might increase the induction of carcinomas both relatively to sarcomas and absolutely. Dose variation may also affect the sex difference and account for some contradictory findings by different authors. Thus Steiner (1942) and Bauer and Byrne (1950) have not found an influence of sex on carcinogenesis, while Heiman and Meisel (1946) , Reuber (1960) and Glucksmann and Cherry (1966) (Cherry and Glucksmann, 1965) produce swellings and tumours, but have not suffered from early ulceration, though secondary ulcers due to malignancy have occurred.
Early ulceration following injection of DMBA in acetone varies in incidence and severity with concentration of the DMBA and sex of the rats (Fig. 1 (Fig. 2 and 3 ) with a peak incidence at around 100 days (Fig. 3) . Significantly more carcinomas occur over a longer period of time in males than in females (61 % ± 5-5 and 28 % ± 6-1 respectively). Fig. 2 and 4 ). Oestrogen reduces the cancer incidence in males from the I % to the % level, while testosterone increases the incidence in females from the I % to the 2 % level. The factor of 2 in the sex difference for carcinomas thus appears to be attributable to the action of the gonadal hormones.
Incidence of sarcomas While carcinomas reach a single peak at about 100 days and subsequently decline to nil by 240 days, sarcomas have an early peak also at 100 days, but subsequently decline only slowly, with some secondary and even tertiary peaks and do not cease to appear before 390 days (Fig. 5) . In some experiments new sarcomas are formed as late as 770 days (Fig. 6) The difference in the pattern of epithelial and mesenchymatous neoplasms is also reflected in a sex difference (Fig. 3) . In males the early peak of sarcomas, like that for carcinomas, is higher than in females and subsidiary peaks tend to be higher, but not of such long duration. While in males only 3 % ± 1-8 of all sarcomas occur after 240 days, in females a significantlv greater percentage do so, i.e. 17 % ± 6-3.
As with carcinomas the sex differences in the incidence of sarcomas vary with dosage of DMBA. At I % the sarcomas in males (91 % ± 6 -1) are significantly more numerous and develop faster than in females (47 % ± 11-5); at I % the total incidence of sarcomas is the same, but they arise more slowly in females; at 2 % there is no difference in incidence nor in duration of the induction perio.-There is again a factor of about 2 in the sensitivity to sarcomas between the sexes: at % about one half as many tumours are formed in females as in males, and at infemales as many neoplasms are induced as at % in males (Fig. 6) In males as many sarcomas are induced by I % as by I or 2 %, but more slowly. As with carcinomas there is no difference in the treatments with I % and 2 %. In females the incidence and speed of sarcoma induction increases with dose from the I % to the 2 % level. The sex and dosage differences in induction rates of sarcomas and carcinomas are illustrated in Fig. 8 . In females sarcomas as well as carcinomas increase with dose and there are always more sarcomas induced than carcinomas. There is strict parallelity in the augmentation with dose of the two tumour types. In males the total incidence of sarcomas is not significantly altered by variations in DMBA dosage, while carcinomas increase only between I % and I % DMBA. At I % and 2 % as many sarcomas as carcinomas appear, and only at I % are there niore sarcomas than carcinomas. For the induction of carcinomas and sarcomas the sex difference is marked at low levels of carcinogenic dosage, but disappears at high doses of DMBA (Fig. 8) .
The difference is thus quantitative rather than qualitative and there is a spectrum of individual sensitivity between males and females with a considerable degree of overlap. Some females respond as fast as males to the same dose of DMBA. The statistical difference between the sexes at lower dose levels is confirmed by such hormonal effects as the reduced tumour induction in males given oestrogens and the increased induction in females given testosterone at equivalent doses of carcinogens. There is a factor of about 2 between the sexes for induction of neoplasms at the 1 % and I % level of DMBA. At the I % level of DMBA in males given oestrogen and females given testosterone the hormonal effect is equivalent to a factor of 2 in carcinogenic dosage.
The sex difference in sensitivity to carcinogens of the salivary glands is not related morphologically to the sexual dimorphism in the structure of the secretory tubules of the submandibular gland. Hardly any carcinomas and no sarcomas arise in these formations. It is feasible, however, that the secretory tubules in males produce substances which promote the growth of epithelial and connectiye tissues in the glandular complex similar to the factors secreted there which promote the growth of nerves and the epidermis (Levi-Montalcini, 1965; Cohen, 1965) . Such factors might also influence the growth of epithelial and sarcomatous tumours and would act in addition to the growth promotion by carcinogens at low doses, though their contribution at high doses of the carcinogen might become negligible.
The carcinogenic effect of DMBA does not appear to be closely related to the toxic action of the compound, though the latter is also sex-linked with females producing twice as many severe early persistent ulcers as males given the same dose ( Fig. 1) . At % DMBA there is no ulceration in either males or females but a highly significant difference between the sexes in the incidence of carcinomas and sarcomas ( Fig. I and 8 ). Conversely at 2 % DMBA ulceration differs significantly between the sexes, but not the percentage of induced tumours ( Fig. I and  8) . The sensitivity to the carcinogenic like that to the toxic action of DMBA varies between the sexes by a factor of 2, but in opposite direction: males respond more to the carcinogenic, but less to the toxic effect of DMBA than females. The transient early ulceration elicited by treatment with 2 % DMBA (Table 11) though sex-linked does not appear to influence subsequent tumour formation supporting the conclusion that the carcinogenic effect of DMBA is independent of the toxic 4action.
The severe persistent ulceration induced by bigger doses of DMBA restricts the range of concentrations which can be explored for careinogenesis. At this site unlike the cervico-vaginal tract, tumour formation increases with dose to a maximum which is reached at 1 % in males and equalled by 2 % in females. There is thus no evidence for an optimal dose phenomenon as described for the incidence of epithelial tumours of the cervico-vaginal tract (Glucksmann and Cherry, 1970a and b).
In both sexes the threshold carcinogenic dose is lower for sarcomas than carcinomas (Fig. 8) ; more sarcomas than carcinomas are induced by the same dose of DMBA up to a maximal level for both which is higher for sarcomas (up to 100 %) than for carcinomas (up to 80 %) in the present series of experiments (Fig. 8) as well as in other experiments performed on castrate animals and with various hormonal administrations; carcinomas do not appear after 240 days (Fig. 2) while sarcomas may appear as late as 770 days (Fig. 6) ; the percentage of epithelial neoplasms induced rises to a single peak, while with the exception of males given 1 % DMBA, sarcomas have two or more peak incidences (Fig. 3, 5, 7) .
Sarcomas are thus induced with smaller doses, in greater number and for a longer time than carcinomas. The histogenesis of these types of tumours may provide an explanation for these differences.
Apart from the immediate death of tissue caused by acetone as solvent for the hydrocarbon, there is a progressive necrosis due to the DMBA deposits acting for prolonged periods which enlarges the lesion. Though with distance the toxic effect of DMBA is diluted, it still prevents the conspicuous fibroblastic reaction following the acute killing by acetone and causes the death of immigrating inflammatory cells. The necrotic tissue is at first incompletely encysted by epithelium growing from the remaining viable glandular structures and this lining protects to some extent immigrating fibroblasts and other mesenchymatous formations which attempt to encapsulate the encysted necrotic tissue with its content of DMBA. Necrosis of such mesenclhymatous elements spreads the lesion and involves adjacent muscles. connective tissue and blood vessels. Carcinomas arise in the lining of the cysts and sarcomas in the stroma of the carcinomas and in the encapsulating mesenchymatous structures which prevent further direct contact between the DMBA deposits and epithelial formationis. Thus only the original encysting epithelium is exposed to carcinogenic risk, while with the expansion of the lesion through progressive necrosis new cellular populations in connective tissue, muscles, blood vessels and perivascular regions are brought under the influence of the more dilute remains of DMBA. Thus the mesenchymatous elemnents have a greater and more prolonged opportunity to react to the carcinogen than the epithelium. There is no need to postulate a differential sensitivity for these elements to carcinogens and indeed the initial peaks of carcinomas and sarcomas are of the samne height (Fig. 3 and 5) , while the subsequent peaks in incidence of sarcomas (Fig. 3, 5 and 7) reflect the prolonged exposure to risk. The fact that peaks occur at intervals instead of a plateau or steadily diminishing incidence, suggests that new populationis of mesenchymatous cells are involved in tumour production.
The sex differeince in the reaction of connective tissues and epithelium appears to be mediated by the sex hormones ( Fig. 4 and 7) which enhance or reduce the sensitivity to carcinogenic action by a factor of 2 and thus equal the sex difference at the lower levels of carcinogenic dosage. Changes in sensitivity or reactivity rather than in adaptability to the effects of DMBA are involved, since persistent as well as transient ulcerations occur more frequently in females than in males, while more neoplasms arise in males than in females. A greater adaptability, i.e. ability to cope and recover froma the noxious effects of DMBA should be reflected in parallel fashion in ulceration and tumour formation, while in fact these two processes appear to be quite distinct from one another.
This study was supported by grants from the Cancer Research Campaign.
